Диссертация (1141198), страница 17
Текст из файла (страница 17)
Efficacy and safety ofunfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and-3 PLUS data..CMAJ. 2006 May 9;174 (10):1421-6;15)Assessment of the Safety and Efficacy of a New Treatment Strategy withPercutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primaryversus tenecteplase-facilitated percutaneous coronary intervention in patients113114with ST-segment elevation acute myocardial infarction (ASSENT-4PCI):randomised trial. Lancet 2006; 367: 569–578;16)Bøhmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety ofimmediate angioplasty versus ischemia-guided management after thrombolysisin acute myocardial infarction in areas with very long transfer distances resultsof the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevationmyocardial infarction). J Am Coll Cardiol.
2010;55:102–10 ;17)Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplastyversus prehospital fibrinolysis in acute myocardial infarction: a randomizedstudy. Lancet. 2002;360:825–9;18)Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primaryangioplastyandpre-hospitalfibrinolysisinacutemyocardialinfarction(CAPTIM) trial: a 5-year follow-up.
Eur Heart J. 2009;30:1598–606;19)Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneouscoronary intervention after fibrinolysis vs. standard therapy in ST-segmentelevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31:2156–69;20)Bradley EH, Curry LA, Spatz ES, et al. Hospital strategies for reducingrisk-standardized mortality rates in acute myocardial infarction.
Ann InternMed. 2012;156:618 –26;21)Bradley EH, Herrin J, Wang Y, et al. Door-to-drug and door-to-balloontimes: where can we improve? Time to reperfusion therapy in patients with STsegmentelevationmyocardialinfarction(STEMI).AmHeartJ.2006;151:1281–7;22)Bradley EH, Nallamothu BK, Herrin J, et al. National efforts to improvedoor-to-balloon time results from the Door-to-Balloon Alliance. J Am CollCardiol. 2009;54:2423–9;11411523)Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 9th Edition;24)Cantor WJ, Fitchett D, Borgundvaag B, et al.
Routine early angioplastyafter fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705–18;25)CARESS-in-AMI study The Lancet, Volume 371, Issue 9629, Pages1997 - 1998, 14 June 2008 ;26)Castaigne AD, Herve´ C, Duval-Moulin AM, et al. Prehospital use ofAPSAC: results of a placebo-controlled study. Am J Cardiol. 1989;64: 30A–33A; discussion 41A–42A;27)Chia S1, Megson IL, Ludlam CAet al. Preserved endothelial vasomotionand fibrinolytic function in patients with acute stent thrombosis or in-stentrestenosis ThrombRes. 2003;111(6):343-9;28)Collet J-P, Montalescot G, Le May M, et al. Percutaneous coronaryintervention after fibrinolysis: a multiple meta-analyses approach according tothe type of strategy. J Am Coll Cardiol.
2006;48:1326–35;29)Collet J-PDerek YF So, Andrew CT Ha, Richard F Davies et al. STsegment resolution in patients with tenecteplase-facilitated percutaneouscoronary intervention versus tenecteplase alone: Insights from the CombinedAngioplasty and Pharmacological Intervention versus Thrombolysis ALone inAcute Myocardial Infarction (CAPITAL AMI) trial Can J Cardiol. 2010 Jan;26(1): 7–1230)COMMIT/CCS-2: Clopidogrel and Metoprolol in Myocardial InfarctionTrial/Second Chinese Cardiac Study -- The Metoprolol Arm Luis Gruberg,MD, FACC Faculty and Disclosures;11511631)Danchin N, Blanchard D, Steg PG, et al.
Impact of prehospitalthrombolysis for acute myocardial infarction on 1-year outcome: results fromthe French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909 –15;32)Danchin N, Coste P, Ferrie`res J. et al. Comparison of thrombolysisfollowed by broad use of percutaneous coronary intervention with primarypercutaneous coronary intervention for ST-segment-elevation acute myocardialinfarction: data from the french registry on acute ST-elevation myocardialinfarction (FAST-MI). Circulation 2008;118: 268–276;33)Dalos Jerjes-Sánchez MD, Úrsulo Juárez-Herrera MD, FACC and TheRENASICA II Investigators; Risk Factors, Therapeutic Approaches, and InHospital Outcomes in Mexicans With ST-Elevation Acute MyocardialInfarction: The RENASICA II Multicenter Registry Clinical Cardiology 2013;36: 241–24834)Davide Capodanno1 and George Dangas. Facilitated/Pharmaco-invasiveApproaches in STEMI Curr Cardiol Rev.
2012 Aug; 8(3): 177–180;35)de Lemos JA, Antman EM, Giugliano RP, et al; Thrombolysis inMyocardial Infarction (TIMI) 14 Investigators. ST-segment resolution andinfarct-related artery patency and flow after thrombolytic therapy. Am JCardiol. 2000;85:299–304;36)De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay totreatment and mortality in primary angioplasty for acute myocardial infarction:every minute of delay counts.
Circulation. 2004;109:1223–5;37)Dieker H-J, Liem SSB, El Aidi H, et al. Pre-hospital triage for primaryangioplasty: direct referral to the intervention center versus interhospitaltransport. JACC Cardiovasc Interv. 2010;3:705–11;38)DiMarioC.1, BologneseL., MaillardL. et al. Combined AbciximabREteplase Stent Study in acute myocardial infarction (CARESS in AMI).Am116117Heart J. 2004 Sep;148(3):378-85;39)ElliottM.Antman,MD; FransVandeWerf,MD,PhD.Pharmacoinvasive Therapy The Future of Treatment for ST-ElevationMyocardial Infarction. Circulation.2004; 109: 2480-2486;40)Elliott M. Antman, MD; Hans W.
Louwerenburg, MD. Enoxaparin asAdjunctive Antithrombin Therapy for ST-Elevation Myocardial InfarctionResults of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial. Circulation.2002; 105: 1642-1649;41)Ellis SG1, Tendera M, de Belder MAet al.1-year survival in arandomized trial of facilitated reperfusion: results from the FINESSE(Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events)trial. JACC Cardiovasc Interv. 2009 Oct;2(10):909-16;42)ESC Guidelines for the management of acute myocardial infarction inpatients presenting with ST-segment elevation.
The Task Force on themanagement of ST-segment elevation acute myocardial infarction of theEuropean Society of Cardiology (ESC). Eur Heart J. 2012; 33: 2569–2619;43)Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardialinfarction: collaborative overview of early mortality and major morbidityresults from all randomized trials of more than 1000 patients. Lancet.1994; 343: 311-322;44)Fleming TR1, Sharples K, McCall J et al. Maintaining confidentiality ofinterimdatatoenhancetrialintegrityandcredibility.ClinTrials. 2008;5(2):157-67;45)Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplastyafter failed thrombolytic therapy for acute myocardial infarction. N Engl J117118Med. 2005;353:2758–68;46)Gibson CM, Cannon CP, Murphy SA, et al.
Relationship of the TIMImyocardial perfusion grades, flow grades, frame count, and percutaneouscoronary intervention to long-term outcomes after thrombolytic administrationin acute myocardial infarction. Circulation. 2002;105: 1909–147)GUSTO IIB investigators. A comparison of reteplasewith alteplase foracute myocardial infarction. N Engl J Med 1997; 337: 1118–1123;48)Halvorsen S, Huber K. The role of fibrinolysis in the era of primarypercutaneous coronary intervention. Thromb Haemost 2011;105:390–395;49)Henry TD, Sharkey SW, Burke MN. Et al.
A regional system to providetimely access to percutaneous coronary intervention for ST-elevationmyocardial infarction. Circulation 2007;116:721-728;50)Herrmann HC, Lu J, Brodie BR, Armstrong PW.etal.Benefitoffacilitated percutaneous coronary intervention in high-risk ST-segmentelevation myocardial infarction patients presenting to nonpercutaneouscoronary intervention hospitals.JACC Cardiovasc Interv 2009;2:917-924;51)Huynh T, Birkhead J, Huber K.
et al. The pre-hospital fibrinolysisexperience in Europe and North America and implications for widerdissemination. JACC Cardiovasc Interv 2011;4:877–883;52)Incidence and Predictors of Bleeding After ContemporaryThrombolytic Therapy for Myocardial Infarction Circulation.1997; 95:2508-2516;53)ISIS-2 (Second International Study of Infarct Survival) CollaborativeGroup. Randomised trial of intravenous streptokinase, oral aspirin, both, orneither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.Lancet 1988; 2:349-60;11811954)J.
Dawn Abbott, MD. Pharmacoinvasive Strategy for ST-SegmentElevation Myocardial Infarction Wading Through the Treatment OptionsCirculation: Cardiovascular Interventions.2010; 3: 294-296;55)Jollis JG, Roettig ML, Aluko AO, et al. Implementation of a statewidesystem for coronary reperfusion for ST-segment elevation myocardialinfarction. JAMA.
2007;298:2371–80;56)Jonathan Afilalo, MD, Arup Michael Roy, MD, and Mark J Eisenberg,MD. Systematic review of fibrinolytic-facilitated percutaneous coronaryintervention: Potential benefits and future challenges. Can J Cardiol. 2009Mar; 25(3): 141–148;57)Kalla K, Christ G, Karnik R. et al. Implementation of guidelinesimproves the standard of care: the Viennese registry on reperfusion strategiesin ST-elevation myocardial infarction (Vienna STEMI registry). Circulation2006;113:2398–2405;58)Keeley EC, Boura JA, Grines CL. Primary angioplasty versusintravenous thrombolytic therapy for acute myocardial infarction: aquantitative review of 23 randomised trials. Lancet. 2003;361:13–20;59)Kelly Neal Wilson.
Strategies for Optimal Cath Lab Staffing. Cath LabDigest Volume 22 - Issue 2 - February 2014;60)L. Wallentin, MD, PhD; P. Goldstein, MD, PhD; P.W. Armstrong,MDet al. Efficacy and Safety of Tenecteplase in Combination With theLow-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin inthe Prehospital Setting The Assessment of the Safety and Efficacy of aNew Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial inAcute Myocardial InfarctionC.B.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
